This field explores TIL therapy. A cancer treatment that proven to be responsive in patients who were non-responsive to the current leading cancer treatment anti-PD1 therapy. In a recent study of Melanoma patients who were non-responsive to anti-PD1 therapy, 49% responded to TIL therapy and 20% were put in complete remission.
Login
Accessing this course requires a login. Please enter your credentials below!